葵花药业
(002737)
| 流通市值：86.32亿 | | | 总市值：86.32亿 |
| 流通股本：5.84亿 | | | 总股本：5.84亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,683,984,047.39 | 1,310,143,325.88 | 663,495,324.67 | 3,377,047,677.27 |
| 营业收入 | 1,683,984,047.39 | 1,310,143,325.88 | 663,495,324.67 | 3,377,047,677.27 |
| 二、营业总成本 | 1,747,427,250.48 | 1,236,684,721.22 | 612,330,871.14 | 2,865,437,208.18 |
| 营业成本 | 1,049,911,737.15 | 801,110,342.62 | 416,109,372.38 | 1,860,974,575.18 |
| 税金及附加 | 28,130,414.92 | 21,302,196.35 | 10,660,668.02 | 49,356,549.45 |
| 销售费用 | 336,479,049.08 | 186,841,827.19 | 82,215,847.3 | 431,006,208.26 |
| 管理费用 | 270,722,708.22 | 185,375,087.68 | 84,457,759.04 | 423,069,390.92 |
| 研发费用 | 66,107,740.22 | 45,181,639.23 | 20,190,757.43 | 124,129,574.53 |
| 财务费用 | -3,924,399.11 | -3,126,371.85 | -1,303,533.03 | -23,099,090.16 |
| 其中:利息费用 | 1,219,173.87 | 775,594.83 | 112,062.84 | 3,562,424.06 |
| 其中:利息收入 | 5,569,374.47 | 4,285,751.95 | 2,008,095.81 | 27,277,742 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 5,084,930.96 | 5,812,389.88 | -348,513.23 | -12,985,379.3 |
| 加:投资收益 | 19,675,919.34 | 10,371,400.62 | 2,905,256.09 | 24,931,696.6 |
| 资产处置收益 | 652,556.91 | 653,722.6 | -10 | -240,150.99 |
| 资产减值损失(新) | -6,839,558.04 | -3,898,447.14 | -1,143,003.3 | -56,930,045.1 |
| 信用减值损失(新) | -3,170,015.65 | -3,625,190.49 | -3,079,516.99 | -5,879,407.57 |
| 其他收益 | 50,388,599.86 | 35,245,703.07 | 23,207,252.3 | 175,736,197.02 |
| 四、营业利润 | 2,349,230.29 | 118,018,183.2 | 72,705,918.4 | 636,243,379.75 |
| 加:营业外收入 | 124,113.98 | 49,921.96 | 56,755.06 | 7,159,700.78 |
| 减:营业外支出 | 8,708,107.01 | 5,606,293.66 | 2,574,897.3 | 8,915,551.98 |
| 五、利润总额 | -6,234,762.74 | 112,461,811.5 | 70,187,776.16 | 634,487,528.55 |
| 减:所得税费用 | 39,679,584.12 | 30,891,877.05 | 11,346,391.34 | 131,756,020.25 |
| 六、净利润 | -45,914,346.86 | 81,569,934.45 | 58,841,384.82 | 502,731,508.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -45,914,346.86 | 81,569,934.45 | 58,841,384.82 | 502,731,508.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -33,538,693.69 | 81,309,905.41 | 57,111,821.08 | 492,045,424.13 |
| 少数股东损益 | -12,375,653.17 | 260,029.04 | 1,729,563.74 | 10,686,084.17 |
| 扣除非经常损益后的净利润 | -81,393,930.98 | 48,185,456.18 | 39,863,790.78 | 344,718,746.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.06 | 0.14 | 0.1 | 0.84 |
| (二)稀释每股收益 | -0.06 | 0.14 | 0.1 | 0.84 |
| 八、其他综合收益 | -26,732.16 | 26,732.16 | -13,366.08 | 122,718.96 |
| 归属于母公司股东的其他综合收益 | -18,712.51 | 18,712.51 | -9,356.26 | 85,903.27 |
| 九、综合收益总额 | -45,941,079.02 | 81,596,666.61 | 58,828,018.74 | 502,854,227.26 |
| 归属于母公司股东的综合收益总额 | -33,557,406.2 | 81,328,617.92 | 57,102,464.82 | 492,131,327.4 |
| 归属于少数股东的综合收益总额 | -12,383,672.82 | 268,048.69 | 1,725,553.92 | 10,722,899.86 |
| 公告日期 | 2025-10-28 | 2025-08-28 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |